Cargando…
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288773/ http://dx.doi.org/10.1186/2051-1426-2-S3-P91 |
| _version_ | 1782352021271085056 |
|---|---|
| author | Kaufman, Howard L Andtbacka, Robert HI Collichio, Frances A Wolf, Michael Li, Ai Shilkrut, Mark Puzanov, Igor Ross, Merrick |
| author_facet | Kaufman, Howard L Andtbacka, Robert HI Collichio, Frances A Wolf, Michael Li, Ai Shilkrut, Mark Puzanov, Igor Ross, Merrick |
| author_sort | Kaufman, Howard L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288773 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887732015-01-15 Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial Kaufman, Howard L Andtbacka, Robert HI Collichio, Frances A Wolf, Michael Li, Ai Shilkrut, Mark Puzanov, Igor Ross, Merrick J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288773/ http://dx.doi.org/10.1186/2051-1426-2-S3-P91 Text en Copyright © 2014 Kaufman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Kaufman, Howard L Andtbacka, Robert HI Collichio, Frances A Wolf, Michael Li, Ai Shilkrut, Mark Puzanov, Igor Ross, Merrick Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial |
| title | Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial |
| title_full | Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial |
| title_fullStr | Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial |
| title_full_unstemmed | Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial |
| title_short | Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial |
| title_sort | association between durable response (dr) and overall survival (os) in patients with unresected stage iiib-iv melanoma treated with talimogene laherparepvec (t-vec) in the phase iii optim trial |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288773/ http://dx.doi.org/10.1186/2051-1426-2-S3-P91 |
| work_keys_str_mv | AT kaufmanhowardl associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT andtbackaroberthi associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT collichiofrancesa associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT wolfmichael associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT liai associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT shilkrutmark associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT puzanovigor associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial AT rossmerrick associationbetweendurableresponsedrandoverallsurvivalosinpatientswithunresectedstageiiibivmelanomatreatedwithtalimogenelaherparepvectvecinthephaseiiioptimtrial |